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Purpose: Enterobacter sakazakii (E. sakazakii) infections
are an important cause of life-threatening meningitis, septicemia,
and necrotizing enterocolitis in infants. Dried infant formula
milk is an important vehicle for E. sakazakii infection. E.
sakazakii was isolated in Korea from dried infant formula
milk. Although E. sakazakii infection of infants may occur in
Korea, its prevalence has not yet been documented. Therefore,
we determined the prevalence of E. sakazakii and documented
symptoms. Materials and Methods: Between March and
October 2006, 1,146 stool samples were collected from
patients at Uijeongbu St. Mary’s Hospital. Each fecal swab
was dissolved in 10 mL of buffered peptone solution, and
enriched culture was streaked onto Druggan-Forsythe-Iversen
(DFI) agar. Presumptive E. sakazakii colonies that exhibited
a blue-green color during culture on DFI medium were
selected. The identity of colonies that developed yellow
pigment during culture on TSA was determined using the
Vitek system and PCR. Results: We isolated 4 E. sakazakii
strains whose 16S rRNA sequence alignments had a similarity
of 99% with those of 3 E. sakazakii ATCC strains.
Conclusion: This is the first report on isolation of E. sakazakii
from stool samples and to document the symptoms of Korean
patients.
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INTRODUCTION
Enterobacter sakazakii (E. sakazakii) is a bacterium
that belongs to the family of Enterobacteriaceae. It
was initially referred to as yellow-pigmented Enter-
obacter cloacae. In 1980, Farmer et al.
1 reclassified
it as E. sakazakii, based on DNA-DNA hybridiza-
tion, biochemical characteristics, antibiotic suscep-
tibility patterns, and presence of yellow-pigmented
colonies.
E. sakazakii infection is an important cause of
life-threatening meningitis (complicated by ventri-
culitis, brain abscess, cerebral infarction, and cyst
formation), septicemia, and necrotizing entero-
colitis in infants.
2,3 Mortality rates of 33 - 80% were
reported for infected patients.
2 There are few
reports of E. sakazakii infection of adults, which is
not usually life threatening.
3-5
E. sakazakii has been isolated from stool and
urine.
6-8 Isolation from stools was demonstrated
in infants aged 18 weeks.
9 This organism has
also been detected in a wide range of foods, in-
cluding cheese, meat, vegetables, grains, herbs,
and spices.
10-12 Most reports are concerned with
the presence of the organism in dried infant
formula milk.
10-13 Dried infant formula milk is an
important vehicle of E. sakazakii infection.
14 In
Korea, E. sakazakii was isolated from 3 of 45
dried infant formula milk samples.
15 Although E.
sakazakii infection of infants may occur in Korea,
its prevalence has not yet been determined.
Therefore, we determined the prevalence of E.
sakazakii in stool samples of hospital patients in
Korea and documented the symptoms of those
whose stool samples were positive for E.
sakazakii.
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by Age Group
Age (yrs) Samples tested (n) Isolates (n)
< 1 392 2
1 - 10 527 0
11 - 20 44 0
21 - 30 18 0
31 - 40 21 0
41 - 50 37 0
51 - 60 23 0
61 - 70 31 2
Over 70 53 0
Total 1,146 4
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MATERIALS AND METHODS
Samples and bacterial strains
To isolate E. sakazakii, 1,146 stool samples were
collected from March to October 2006 at Uijeongbu
St. Mary's Hospital.
Each fecal swab from each sample was dis-
solved in 10 mL of buffered peptone solution
(Oxoid, Basingstroke, England) and incubated at
37°C for 24 hours. One mL of preenriched buf-
fered peptone solution was added to 10 mL of
enterbacter enrichment broth (Oxoid) and in-
cubated at 37°C for 24 hours. The enriched culture
was streaked onto Druggan-Gorsythe-iversen
(DFI) medium (Oxoid) and incubated at 37°C for
24 hours. Up to five presumptive E. sakazakii
colonies that exhibited a blue-green color during
culture on DFI medium were selected for culture
on TSA at 25°C for 72 hours. The identities of
colonies that developed yellow pigment during
culture on TSA were determined using a Vitek
GNI card (bio Meriux, Marcyl’ Etoile, France) and
PCR. E. sakazakii ATCC 29004, E. sakazakii ATCC
29544, and E. sakazakii ATCC 51329 were used as
positive controls.
16S rRNA gene amplification and direct sequencing
Bacteria were grown on TSA at 37°C for 24
hours. One loop of biomass was scraped off the
agar, suspended in 500 L of sterile distilled water, μ
and boiled for 10 minutes. After centrifugation at
1200 × g for 10 minutes at 4°C, the supernatants
were used as templates for PCR. To detect the
sequence of the 16S rRNA gene, E. sakazakii strains
were amplified using PCR assays with Esakf (5'
GCT YTG CTG ACG AGT GGC GG 3') and Esakr
(5' ATC TCT GCA GGA TTC TCT GG 3'), details
of which have previously been reported.
7
The following conditions were used for the
thermal cycler (PTC-100; MJ Research, Watertown,
MA, USA): initial denaturation for 2 minutes at 94
°C, 29 cycles of denaturation at 94°C for 30 seconds,
annealing at 60°C for 60 seconds, extension at 72°C
for 90 seconds, and a final cycle at 72°C for 5
minutes. The products were then sequenced using
a modified Sanger method, a Big-dye kit (Applied
Biosystems), and an ABI 3,730 capillary DNA
analyzer (Applied Biosystems, Foster City, CA,
USA).
Antibiotic susceptibility testing
The antibiotic susceptibility of E. sakazakii was
determined using the Vitek system and GNS
cards. The following antibiotics were tested: ami-
kacin (AN), ampicillin (AM), ampicillin/sulbactam
(SAM), aztreonam (AZ), cefazolin (CZ), cefepime
(FEP), cefoxitin (CFX), ciprofloxacin (CIP), genta-
micin (GM), imipenem (IPM), piperacillin/tazob-
actam (TAZ), and trimethoprime-sulfamethoxazole
(SXT).
RESULTS
Four E. sakazakii strains were isolated from 1,146
stool samples of Korean patients. Details of stool
samples and isolated strains are shown in Table
1. E. sakazakii was isolated from 2 of 392 infants
less than one year of age. Among adults, 2 E.
sakazakii strains were isolated from 61 - 70-year-old
age group. The 4 clinical isolates and 3 ATCC
strains were tested for antibiotic resistance. Strains
isolated from babies less than one year of age were
resistant to ampicillin and cefazolin, whereas
isolates from adults were susceptible to all anti-
biotics tested. The clinical characteristics of the 4
cases were as follows.Surveillance for Stool Enterobacter Sakazakii
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Case 1
A 3-month-old baby who exhibited symptoms of
poor nutrition and abdominal distention was
hospitalized, and a clinical diagnosis of gastroen-
teritis and meningitis was made. The white blood
cell (WBC) count of cerebrospinal fluid (CSF) was
16 per mm
3 and consisted of lymphocytes (82%),
monocytes (12%), and neutrophils (6%). CSF
agglutination tests for Streptococcus agalactiae, S.
pnemoniae, Neisseria meningitidis, and H. influenza
type B were negative. Blood and CSF cultures were
negative. Intravenous therapy with amoxicillin/
clavulanate and tobramycin was initiated and the
patient's condition gradually improved after 10
days of hospitalization. Rotavirus antigen and E.
sakazakii were isolated from stool specimens on day
7 of hospitalization.
Case 2
A 20 days-old baby presented with fever. He
was hospitalized with a clinical diagnosis of sepsis
and meningitis. The patient's physical condition on
admission was normal except for the presence of
jaundice. Intravenous therapy with ampicillin/
sulbactam and tobramycin was initiated, and the
patient's condition gradually improved after 5
days of hospitalization. A diagnostic lumbar
puncture revealed that CSF had a total protein
concentration of 81 mg/dL, a glucose concentra-
tion of 62 mg/dL, and a WBC of 2 per mm
3. CSF
agglutination tests for Streptococcus agalactiae, S.
pnemoniae, Neisseria meningitidis, and H. influenza
type B were negative. Blood and CSF cultures were
negative. E. sakazakii was isolated from stool
specimens after 4 days of hospitalization.
Case 3
A 64 years-old male patient presented with right
hemiplegia and thymic cyst rupture. E. sakazakii
was isolated from stool specimens on day 30 of
hospitalization. No sign or symptom indicative of
E. sakazakii infection was observed during hospi-
talization.
Case 4
A 72 years-old male patient was diagnosed with
intracranial hemorrhage. E. sakazakii was isolated
from stool specimens on day 30 of hospitalization.
No sign or symptom indicative of E. sakazakii
infection was observed during hospitalization.
The biochemical and antibiotic resistance cha-
racteristics of the isolates are presented in Table
2. Three of the 4 isolates produced yellow
pigmentation during culture on TSA. Moreover, all
4 isolates exhibited a blue-green color during
culture on DFI agar, which confirmed the con-
stitutive expression of -glucosidase (data not ɑ
shown). Three of the Vitek GNI biochemical
profiles of isolates identified as E. sakazakii had
identification values of 96 - 99% and that of one
strain was 82% (S2, Table 2). There were several
point mutations in the sequences of the strains
(Table 3).
Table 2. Characteristics, Antimicrobial Susceptibilities, and Identification by Vitek GNI of E. sakazakii Strains
Isolates Age (yrs) Sex Vitek GNI (%) Antibiotic resistance
Case 1 (S1) < 1 M 96 Am
r, CZ
r
Case 2 (S2) < 1 M 82 Am
r, CZ
r
Case 3 (S3) 64 M 99 Am
s, CZ
s, CFX
s
Case 4 (S4) 70 M 99 Am
s, CZ
s, CFX
s
ATCC 29004 99 Am
r, CFX
r
ATCC 27544 96 Am
r
ATCC 51329 97 CZ
r, CFX
r
M, male; Am
r, ampicillin resistant; Am
s, ampicillin susceptible; CZ
r, cefazolin resistant; CZ
s, cefazolin sensitive; CFX
r, cefoxitin
resistant; CFX
s, cefoxitin sensitive.Jung Beom Kim, et al.
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DISCUSSION
We isolated four E. sakazakii strains from 1,146
stool samples. Clinical outbreaks of E. sakazakii
infection in neonatal care units in various parts of
the world have been reported.
16,17 However, isola-
tion of E. sakazakii from humans in Korea has never
been documented before.
All four isolates developed blue-green colonies
on DFI agar, confirming the constitutive ex-
pression of -glucosidase. However, -glucosidase ɑ ɑ
activity is not restricted to E. sakazakii.
18
E. sakazakii is naturally resistant to all macro-
lides, lincomycin, clindamycin, streptogramins,
rifampicin, fusidic acid, and fosfomycin.
18 It is,
however, susceptible to some antibiotics, including
tetracyclines, aminoglycosides, numerous -lactams, ɑ
chloramphenicol, antifolates, and quinolones.
19
Our results showed that strains of E. sakazakii
isolated from adults were sensitive to ampicillin
and cefazolin. However, the strains of E. sakazakii
isolated from infants were resistant to ampicillin
and cefazolin. These observations are different
from those of Mustjens et al., who showed that the
resistance to ampicillin is likely due to exclusion
of E. sakazakii.
20 We speculate that specific virulence
factor could explain the differences in suscepti-
bility between the strains isolated from infants and
those from adults. But, further study is needed to
confirm the differences in antibiotic suscepti-
bilities.
Several studies on the molecular characteriza-
tion of E. sakazakii have been conducted to identify
phylogenetic relationships and suitable PCR
primers.
19,21-23 The 16S rRNA gene has widely been
used for sequence analysis because it is highly
conserved and ubiquitous. Amplification of the
16S rRNA gene from the E. sakazakii isolates using
the Esakf and Esakr primer pair produced PCR
products with 929 bp long (Fig. 1). These primers
are very specific for E. sakazakii.
19 Molecular
methods based on 16S rRNA gene sequencing are
well established and are routinely used for
characterization and identification of bacteria.
24,25
The 16S rRNA gene contains variable and hyper-
variable regions. The variable regions have been
used to discriminate between species and genera.
Variability in the E. sakazakii 16S rRNA gene has
also been observed. Lehner et al.
19 detected 2 phylo-
genetically distinct lineages in the 16S rRNA gene,
and Hassan et al.
26 observed sequence differences
between E. sakazakii and other Enterobacteriaceae
within hypervariable regions. We compared the
16S rRNA sequences of the 4 isolates with those
of the three ATCC strains. The sequence
alignments of the 16S rRNA PCR products of the
4 isolates and the 3 E. sakazakii ATCC strains had
Table 3. Sequence Analysis of the 16 S rRNA Genes of E. sakazakii Strains Isolated from Stool Samples and Those
of ATCC 29544, ATCC 51329, and ATCC 29004 Strains of E. sakazakii
Strain E. sakazakii 16S rRNA gene sequence polymorphisms
S1
S2
S3
S4
TTCGGAC TGTTGTGGTTAATAACCGCAGCA CTGTTAAGTCA TTGAAACTGGCAG
TTCGGAC CGTTGTGGTTAATAACCGCAGCA TGATTAAGTCA TTGAAACTGGTCA
TTCGGAC TGTTGTGGTTAATAACCGCAGCA CTGTTAAGTCA TTGAAACTGGCAG
TACGGAC CGTTGTGGTTAATAACCGCAGCA CTGTTAAGTCA TTGAAACTGGCAG
E. sakazakii ATCC 29544
E. sakazakii ATCC 51329
E. sakazakii ATCC 29004
TACGGAC TGTTGTGGTTAATAACCGCAGCA TGATTAAGTCA TTGAAACTGGTCA
GCAAGAC GGTTAAGGTTAATAACCTTGGCC CTGTTAAGTCA CCGAAACTGGCAG
TTCGGAC TGTTGTGGTTAATAACCACAGCA CTGTTAAGTCA TTGAAACTGGCAG
Fig. 1. Agarose gel analysis of 16S rRNA PCR products of
E. sakazakii strains.Surveillance for Stool Enterobacter Sakazakii
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99% similarity. However, we detected several
point mutations in the sequences (Table 3). The
present result together with previous study
19 in-
dicate that the E. sakazakii 16S rRNA gene has at
least 4 "hot spots" and may contain several point
mutations. A few cases of E. sakazakii infection in
adult have been reported, and younger than 4
years old infants and children are high risk groups
compared with adults.
10
In this study, infection signs of E. sakazakii were
encountered in only 2 patients, however, not seen
in adults. This result shows that E. sakazakii
infection is more risky in infants than in adults.
Powdered infant formula is both the vehicle and
the direct/indirect source of 50 - 80% cases of
diseases caused by E. sakazakii.
14 Therefore, we
suggest that dried infant formula milk in the
present study could be considered as the possible
sources of E. sakazakii isolated from infants, al-
though we were unable to prove our hypothesis.
Finally, our study shows that E. sakazakii infection
does occur in Korea.
In conclusion, this study is the first to report the
isolation of E. sakazakii from stool samples of
Korean patients and indicates that continuous
surveillance is needed to monitor E. sakazakii in-
fection.
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